Consumer Staples
Biome Australia Limited (BIO)
Biome Australia Limited (ASX: BIO) is an Australian health company specializing in evidence-based natural medicines, particularly within the gut health and microbiome sector. They develop and market a range of practitioner-grade probiotic supplements, primarily under their Activated Probiotics® brand, sold through pharmacies, health practitioners, and direct-to-consumer channels in Australia and increasingly internationally.
Market Cap
A$87M
Shares on Issue
N/A
Price Chart
AI Analysis
Biome Australia is a rapidly growing small-cap player in the global gut health market, leveraging increasing consumer awareness of the microbiome's impact on overall health. Since its listing in late 2021, the company has focused on expanding its distribution footprint and product portfolio within the lucrative health and wellness sector. Recent performance has likely shown strong revenue growth driven by increased product penetration and online sales, though profitability may still be nascent as the company invests heavily in marketing, research, and international expansion efforts. Key metrics would include customer acquisition cost, recurring revenue growth, and gross profit margins on its product lines.
The growth outlook for Biome Australia is tied to the accelerating demand for scientifically-backed natural health products and the expansion of its Activated Probiotics® range into new therapeutic areas. Upcoming catalysts could include successful launches into new international markets (e.g., Asia or North America), securing significant new distribution agreements with major pharmacy chains, or positive outcomes from further clinical studies validating their product efficacy. Strategically, the company is focused on building brand equity, enhancing its scientific credentials, and expanding its global reach to capitalise on the structural tailwinds of the preventative health movement.
Bull Case
- • Rapid expansion into high-growth international markets, significantly increasing revenue streams beyond Australia.
- • Successful development and commercialization of new, differentiated probiotic formulations based on cutting-edge microbiome science.
- • Strong brand building and customer loyalty for its Activated Probiotics® range, leading to high recurring revenue and reduced marketing costs over time.
Bear Case
- • Intense competition from larger pharmaceutical companies and established health supplement brands with greater marketing budgets and distribution networks.
- • Regulatory hurdles or changes in health claims standards that could impact product marketing or require costly reformulation.
- • Failure to scale manufacturing or supply chain effectively to meet growing demand, leading to operational inefficiencies or stockouts.
Recent Announcements
Biome Half Year Results and Webinar
H1 FY26 Results & Company Presentation
Biome First Half FY26 Results and Highlights
🚨 Price SensitiveBiome First Half FY26 Results and Highlights
Appendix 4D & Half Yearly Report
🚨 Price SensitiveAppendix 4D & Half Yearly Report
Expiry of Unlisted Options
FAQs
What does BIO do?
Biome Australia Limited specialises in developing, manufacturing, and marketing evidence-based natural medicines, with a core focus on gut health through its range of probiotic supplements. Their flagship Activated Probiotics® products are designed to support various health conditions by modulating the human microbiome, sold through pharmacies and health professionals.
Is BIO a good investment?
Investing in Biome Australia involves both opportunities and risks inherent to small-cap growth companies in a dynamic sector. The company benefits from strong tailwinds in the gut health market and a growing portfolio of scientifically-backed products. However, investors face risks from intense competition, the need for sustained market penetration, and the speculative nature of early-stage profitability, requiring careful due diligence on its execution capability and financial health.
What drives BIO's share price?
Biome Australia's share price is primarily driven by its sales growth trajectory, successful market expansion (especially internationally), positive updates on new product development and clinical validation, and its pathway to sustainable profitability. Broader consumer health trends, investor sentiment towards small-cap growth stocks, and the competitive landscape within the natural medicine sector also play significant roles.
Key Metrics
Related Stocks
Consumer Staples
A2MThe A2 Milk Company Limited
A$9.58
17.1% 1Y
The A2 Milk Company Limited operates in the consumer staples sector, focusing on milk and related products. It develops, markets, and distributes A2 dairy products, primarily in New Zealand, Australia, China, and the United States. Key products include A2 Ultra millions, A2 Organic milk, and infant formula.
Consumer Staples
AACAustralian Agricultural Company Limited.
A$1.32
-7.7% 1Y
Australian Agricultural Company (AAC) is one of Australia's largest beef producers and landholders, primarily focused on breeding, raising, and marketing Wagyu and other premium beef brands. Operating vast cattle stations across Northern Australia, the company manages the full supply chain from pasture to plate, including properties, cattle, and feedlots. Its key products include high-quality Wagyu beef sold globally under brands like Master Kobe and Wylarah.
Consumer Staples
AAPAustralian Agricultural Projects Limited
A$0.05
19.5% 1Y
Australian Agricultural Projects Ltd is an agribusiness company focused on the management and operation of olive groves in Victoria, Australia. The company's primary activities involve the harvesting and processing of olives to produce premium extra virgin olive oil for both domestic and international markets. Additionally, AAP provides horticultural management and consulting services for its own and third-party agricultural assets.